The Wegovy Pill Is Now EU-Approved: What It Means for Irish Patients

All medical information is reviewed by our clinical partners at MedicOnline.

Dr. Jahan Khan, CMO @ MedicOnline

IMC 409788

On 15 July 2026, the European Commission granted marketing authorisation for the Wegovy pill, making oral semaglutide the first GLP-1 receptor agonist tablet approved for weight management anywhere in the European Union. The decision followed a positive recommendation from the EMA's Committee for Medicinal Products for Human Use on 21 May 2026 and applies to all 27 EU member states, including Ireland.

This is a significant development for Irish patients. For the first time, a clinically proven weight management medication with results broadly comparable to injectable Wegovy will be available in a once-daily tablet.

This article explains what EU approval means in practice, what still needs to happen before Irish patients can get a prescription, how the pill compares with treatments already available here and what to do now if you are considering medical weight management. For the full background, including the clinical trial data and regulatory timeline, see our comprehensive guide to the Wegovy pill in Ireland.

All GLP-1 medications are prescription-only in Ireland. Treatment is subject to clinical assessment by an IMC-registered doctor. Not everyone is eligible and a prescription is not guaranteed.

What Exactly Was Approved?

The European Commission authorised oral semaglutide 25mg, under the Wegovy brand, for adults living with obesity (a BMI of 30 or above) or overweight (a BMI of 27 to 29.9) with at least one weight-related health condition. These conditions can include high blood pressure, type 2 diabetes or prediabetes, high cholesterol or cardiovascular disease. The pill is approved alongside a reduced-calorie diet and increased physical activity, the same indication as the existing Wegovy injection.

The approval covers four tablet strengths used during dose escalation: 1.5mg, 4mg, 9mg and the 25mg maintenance dose. It contains the same active ingredient, semaglutide, as the Wegovy injection and Ozempic, but is a higher-dose oral formulation developed and licensed specifically for weight management.

Alongside the pill, the European Commission also approved a Wegovy 7.2mg injectable dose in a single-dose pen. In the STEP UP trials, this higher dose showed average weight loss of approximately 20.7%, with one in three participants achieving weight loss of 25% or more.

The Approval Trail

Novo Nordisk's OASIS clinical trial programme studied oral semaglutide 25mg in approximately 1,300 adults with obesity or overweight. In the pivotal OASIS 4 trial, a 64-week Phase 3b study, participants taking the pill achieved average weight loss of 13.6%, compared with 2.2% in the placebo group. In the treatment-adherent analysis, weight loss reached 16.6%, and roughly one in three participants lost 20% or more of their body weight.

What EU Approval Means for Ireland

The EU marketing authorisation is a legal licence. It means the Wegovy pill has met the EMA's standards for safety, efficacy and quality, and it can be prescribed in Ireland for its approved indication. However, a legal licence is only the first of several steps before someone can collect the medication from an Irish pharmacy.

Why You Cannot Safely Get It Early

It may be tempting to order the pill from a website or a pharmacy outside Ireland. However, importing prescription medicines into Ireland by post or courier is illegal. The HPRA and Revenue Customs actively intercept these parcels. In 2025, the HPRA detained more than 763,000 dosage units of falsified and illegal medicines, with a significant proportion involving GLP-1 products.

The risks go beyond legality. Products sourced outside the regulated Irish pharmacy supply chain have no guarantee of authenticity, correct storage or appropriate dosing. The HPRA warns that consumers can have no guarantees about the safety, quality or authenticity of prescription medicines obtained outside a regulated pharmacy setting.

The only safe route will be a prescription from an Irish-registered doctor, dispensed by a licensed Irish pharmacy, after the product has launched here.

At Bua Health, prescriptions are issued by IMC-registered doctors through our clinical partner MedicOnline and dispensed through a regulated pharmacy network in the Republic of Ireland. Learn how the programme works.

How the Pill Works

Dose escalation schedule

The Wegovy pill uses a four-step titration over approximately 90 days before reaching the maintenance dose. This gradual approach is designed to reduce gastrointestinal side effects, which are most common when starting treatment or increasing the dose.

How to take it

The daily routine is more specific than for many oral medicines. Semaglutide is a peptide and the tablet uses an absorption enhancer that works properly only in a fasting stomach with minimal water.

• Take one tablet first thing in the morning on an empty stomach, after fasting for at least eight hours.
• Swallow it whole with up to 120ml of plain water.
• Wait at least 30 minutes before eating, drinking anything else or taking other oral medication.
• Do not crush, chew or split the tablet.

If you eat too soon, drink coffee with the tablet or take other pills at the same time, absorption can fall and the medication may not work as intended. For some people this will be straightforward, while others may find a weekly injection more practical. A clinician can help you consider these differences during assessment.

Side effects

The side effect profile closely mirrors injectable Wegovy. The most commonly reported effects in the OASIS trials were nausea, diarrhoea, constipation and occasional vomiting. These are often most noticeable during dose escalation and may settle as the body adjusts. Serious side effects are uncommon but can include pancreatitis, gallbladder problems and, for people with diabetic retinopathy, changes in vision.

How It Compares With Current Irish Options

Injectable Wegovy and Mounjaro are available in Ireland on private prescription. Both are clinically proven to support significant, sustained weight loss when used with dietary and lifestyle changes.

There is no universally best option. The appropriate treatment depends on your health profile, medical history, lifestyle and a clinician's recommendation after a full assessment. For more detail, read our comparison of Wegovy and Mounjaro in Ireland.

The medication that suits you is a clinical decision, not a consumer choice. Doctors assess every patient individually, and not everyone will be suitable for treatment.

What Should You Do Right Now?

If you have been waiting for the Wegovy pill, that is understandable. However, there is no confirmed Irish launch date. If you are clinically eligible for weight management treatment now, starting an injectable option and discussing a possible switch later may be more appropriate than delaying indefinitely.

Modern Wegovy and Mounjaro pens are pre-filled, use a short needle and take seconds to administer. If needle anxiety is the main barrier, it is worth raising this in a consultation so a clinician can discuss the options and support available.

• If you are not on treatment: complete a free two-minute assessment. If appropriate, you can be invited to a remote GP consultation. The Bua programme costs €50 per month, excluding medication, and you may be able to claim tax relief of up to 20% on treatment costs.
• If you are already a Bua patient: continue your current plan and raise the pill at your next clinical check-in if you think it may suit your routine in future.
• If you are considering switching providers: read our guide to switching weight loss treatment providers in Ireland.

Related Reading

• The Wegovy Pill in Ireland: EU Approved, But When Will You Actually Get It?
• Do I Qualify for Wegovy in Ireland?
• Wegovy vs Mounjaro in Ireland

Sources and References

• Novo Nordisk. European Commission approval of Wegovy pill as first oral GLP-1 for weight management in the EU. 15 July 2026.
• European Medicines Agency. CHMP positive opinion: Wegovy variation for oral tablet formulation. 22 May 2026.
• Novo Nordisk. Wegovy pill approved in the UK by the MHRA. 11 June 2026.
• Novo Nordisk. FDA approval of oral Wegovy for weight management. 22 December 2025.
• Wharton S, et al. Oral Semaglutide at a Dose of 25mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine. 2025;393(11):1077-1087.
• HPRA. Dangers of buying prescription medicines online.
• Irish Revenue. Importation and exportation of medicinal products and unauthorised counterfeit medical preparations.

Related Blogs

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read

Who Qualifies for Mounjaro in Ireland?

An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.

Read

What weight loss injections are available in Ireland?

A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026

Read

Who can't take Mounjaro? Understanding the contraindications

A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.

Read